Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma
Public ClinicalTrials.gov record NCT04972942. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I Trial of Targeted Immunotherapy With Daratumumab Following Myeloablative TBI-Based Conditioning and AlloHCT in Children, Adolescents and Young Adults With High Risk T-Cell Acute Lymphoblastic Leukemia and Lymphoma (ALLO-T-DART)
Study identification
- NCT ID
- NCT04972942
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 30 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- Up to 39 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 21, 2023
- Primary completion
- Aug 31, 2027
- Completion
- Aug 31, 2028
- Last update posted
- Apr 14, 2026
2023 – 2028
United States locations
- U.S. sites
- 16
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Phoenix Children's Hospital | Phoeniz | Arizona | 85016 | Not yet recruiting |
| Loma Linda University Children's Hospital | Loma Linda | California | 92354 | Recruiting |
| University of California | Los Angeles | California | 90095 | Not yet recruiting |
| University of California | San Francisco | California | 94143 | Recruiting |
| Children's Hospital Colordao | Aurora | Colorado | 80045 | Not yet recruiting |
| Children's National Medical Center | Washington D.C. | District of Columbia | 20010 | Not yet recruiting |
| University of Florida | Gainsville | Florida | 32608 | Recruiting |
| John Hopkins All Children's Hospital | St. Petersburg | Florida | 33701 | Not yet recruiting |
| Riley Children's Hospital | Indianapolis | Indiana | 46202 | Recruiting |
| Boston Children's Hospital | Boston | Massachusetts | 02115 | Recruiting |
| Helen DeVos Children's Hospital | Grand Rapids | Michigan | 49503 | Recruiting |
| New York Medical College | Vallhala | New York | 10595 | Recruiting |
| Nationwide Children's Hosptial | Columbus | Ohio | 43205 | Not yet recruiting |
| Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104 | Recruiting |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Not yet recruiting |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated T-Cell Acute Lymphoblastic Lymphoma trials
Other public records listing T-Cell Acute Lymphoblastic Lymphoma. Sorted by last update posted; newest first. Not a recommendation.
- NCT07220993: Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells Recruiting
- NCT03690011: Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells Recruiting
- NCT03081910: Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04972942, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 14, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04972942 live on ClinicalTrials.gov.